Pathology: es-BC - HR-positive - 1st line (L1); la/mBC - HR positive; la/mBC - HR positive - (neo)adjuvant (NA); la/mBC - HR positive - L2 - all population; la/mBC - HR positive - L2 - PIK3CA mutant; la/mBC - HR-positive - 2nd line (L2);
| es-BC - HR-positive - 1st line (L1) | la/mBC - HR positive | la/mBC - HR positive - (neo)adjuvant (NA) | la/mBC - HR positive - L2 - all population | la/mBC - HR positive - L2 - PIK3CA mutant | la/mBC - HR-positive - 2nd line (L2) | ||||||
| LORELEI, 2019 | BELLE-2 (patients with known PI3K status), 2017 | NEO-ORB (wild type cohort), 2019 | NEO-ORB (mutant cohort), 2019 | NEO-ORB (buparlisib vs placebo), 2019 | BELLE-2 (full population), 2017 | BELLE-2 (PI3K pathway activated), 2017 | SOLAR-1 (patients with PIK3CA mutant status), 2019 | SOLAR-1 (patients without PIK3CA mutant status), 2019 | BELLE-3, 2018 | ||
| buparlisib plus fulvestrant | 4 | T1 | T1 | T1 | T1 | ||||||
| alpelisib plus letrozole | 2 | T1 | T1 | ||||||||
| alpelisib plus fulvestrant | 2 | T1 | T1 | ||||||||
| taselisib plus letrozole | 1 | T1 | |||||||||
| buparlisib plus letrozole | 1 | T1 | |||||||||
| letrozole | 0 | T0 | T0 | T0 | T0 | ||||||
| fulvestrant | 0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||